Select Page

cure for dry eyes

Who gets dry eyes?

People who wear disposable contacts and reach middle age often find that their favorite brand or type of contacts no longer feel comfortable.  

Not because they have outgrown contacts now that they have reached their 40’s, but because of one of the most common complaints ophthalmologists hear from patients—dry eyes.  Contact lenses can aggravate dry eyes and leave patients with irritated, red eyes.  With such a common complaint, many people wonder if there is a cure for dry eyes.

Sources of Moisture in the Eyes

There are only a few sources of moisture in the eyes.  The lacrimal gland is located in the upper outer quadrant of the eye.  This gland produces the river of tears when someone cries or gets something in their eye.

Another source of moisture in the eyes include a network of glands embedded in the white surface of the eye and under the surface of the eyelids, called the conjunctiva.  These important glands produce water and mucus which keep the eye from drying out.

Finally, the glands at the edge of the lids produce an oily substance that keep the eye lubricated.  When mixed with the water and mucus from the conjunctiva, this tear film on the surface of the eye allows for proper vision.  Every time a person blinks, this mixture is reapplied to the surface of the eye. Keeping the eye moist and protected.

Lack of Tears

The tear production in the eyes tends to slow as a person ages.  For women, menopause is one of the major reasons for dry eyes.  If the tear producing lacrimal glands don’t make tears as they once did, there will be a problem with the amount of tears.  When either of the other two glands slow, the result is dry eye syndrome.  A lack of tear film on the eye can leave a person with a feeling of burning or grittiness in their eyes.

Other Causes of Dry Eye Syndrome

In addition to aging, there are many other causes of dry eye syndrome.  These include:

  • Side effect from antihistamines, blood pressure medicines, or other medications
  • Thyroid problems, rheumatoid arthritis, Parkinson’s disease, Sjögren’s syndrome, diabetes, or other underlying conditions
  • Exposure to irritating environmental pollutants such as dust, smoke, or pet dander
  • Eye surgery
  • Contact lens use
  • Staring at a computer screen, phone, or television for too long without blinking and replenishing the tear film

Computer Vision Syndrome

A dry eye syndrome culprit not seen much until the 21st century is known as computer vision syndrome.  This is caused from staring at the computer screen for long periods of time and blinking less.  Since the eyes are open more of the time, they tend to dry out since the lack of blinking does not refresh the surface of the eye with lubricating tears.  Symptoms of this new cause include blurry or double vision.

How to Treat Dry Eyes

Soothing dry eyes is not only for comfortable vision, but it can also help to avoid infections and scarred corneas. The treatment options for dry eye syndrome include:

  • Warm compresses
  • Gentle eye massage that help to stimulate the oil glands on the lids
  • Artificial tears which bring temporary relief
  • Certain medicines
  • Placement of tear drainage ducts into the tear duct to block excessive tear drainage
  • TheraLife products for dry eye syndrome – to restore tear functions inside out.

Some sufferers do not want to undergo an uncomfortable office visit, put up with endless applications of artificial tears which can actually dry the eyes out even more, or take medicines to relieve their dry eyes.  They opt for a more natural solution, TheraLife.

TheraLife – A Leader in Chronic Dry Eye Relief

TheraLife goes directly to the source of the problem of dry eyes-lack of tear production.  With their entire line of natural dry eye relief products, TheraLife addresses the fundamental cause of dry eyes: underactive tear secretion.  By targeting the issue of decreased tear production from the inside out with natural methods,

TheraLife promotes the production of the body’s own healing tears without the use of artificial tears, medications, or surgical procedures.

With an all-natural, unique proprietary formula, TheraLife is clinically proven to provide relief for 80% of first-time users.  By increasing intracellular metabolism, membrane permeability, and micro-circulation of the blood, the meibomian, lacrimal, and goblet cells that makeup the tear glands area able to secrete their own tears naturally helping to overcome dry eye syndrome issues.  

Painful inflammation and dryness is eliminated when the body is able to naturally produce tears.  Restoration of comfortable vision is possible with TheraLife’s line of all natural products that address the root cause of dry eye.  End reliance on drops or medicine and restore comfortable vision for the eyes with TheraLife.

To learn more, 

Call and talk to a doctor toll free 1-877-917-1989 US/Canada.  International (650) 949-6080.  Email to:  [email protected]

REFERENCES

1. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221–232. 
2. Lemp MA, Chacko B. Diagnosis and treatment of tear deficiencies. In: Tasman W, Jaeger E, editors. Duane’s Clinical Ophthalmology. Philadelphia: Harper and Row; 1997.
3. Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584–589. 
4. Schein OD, Muñoz B, Tielsch JM, Bandeen-Roche K, West S. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723–728. [
5. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268. 
6. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114–1119. 
7. Yazdani C, McLaughlin T, Smeeding JE, Walt J. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672–1682. [
8. Brewitt H, Sistani F. Dry eye disease: the scale of the problem. Surv Ophthalmol. 2001;45:S199–S202. [PubMed[]
9. Ohashi Y, Ishida R, Kojima T, Goto E, Matsumoto Y, Watanabe K, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol. 2003;136:291–299.
10. Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292. 
11. Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology. 1998;105:2327–2329. 
12. Jones DT, Monroy D, Ji Z, Atherton SS, Pflugfelder SC. Sjögren’s syndrome: cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium. Invest Ophthalmol Vis Sci. 1994;35:3493–3504. 
13. Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol. 2008;19:287–291. 
14. Tuft S, Lakhani S. Medical management of dry eye disease. Dev Ophthalmol. 2008;41:54–74.
15. Kymionis GD, Bouzoukis DI, Diakonis VF, Siganos C. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829–836. 
16. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol. 2008;19:535–540. 
17. Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008;27:S25–S30. 
18. Geerling G, Brewitt H. Flow chart on surgical approaches to dry eye. Dev Ophthalmol. 2008;41:313–316. 
19. Dursun D, Kim MC, Solomon A, Pflugfelder SC. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline and corticosteroids. Am J Ophthalmol. 2001;132:8–13. 
20. Liden J, Rafter I, Truss M, Gustafsson JA, Okret S. Glucocorticoid effects on NF-kappaB binding in the transcription of the ICAM-1 gene. Biochem Biophys Res Commun. 2000;273:1008–1014. 
21. Aksoy MO, Li X, Borenstein M, Yi Y, Kelsen SG. Effects of topical corticosteroids on inflammatory mediator-induced eicosanoid release by human airway epithelial cells. J Allergy Clin Immunol. 1999;103:1081–1091.
22. Djalilian AR, Nagineni CN, Mahesh SP, Smith JA, Nussenblatt RB, Hooks JJ. Inhibition of inflammatory cytokine production in human corneal cells by dexamethasone, but not cyclosporin. Cornea. 2006;25:709–714.
23. Pflugfelder SC, Maskin SL, Anderson B, Chodosh J, Holland EJ, De Paiva CS, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138:444–457. 
24. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjögren syndrome. Ophthalmology. 1999;106:811–816.
25. Wachtel M, Frei K, Ehler E, Fontana A, Winterhalter K, Gloor SM. Occludin proteolysis and increased permeability in endothelial cells through tyrosine phosphatase inhibition. J Cell Sci. 1999;112:4347–4356. 
26. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119–125. 
27. Gündüz K, Ozdemir O. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol (Copenh) 1994;72:438–442. 
28. Laibovitz RA, Solch S, Andriano K, O’Connell M, Silverman MH. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315–323. 
29. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107:967–974.

Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

Pin It on Pinterest